An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Phamacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (WAIHA) or Cold Agglutininin Disease (CAD)

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Phamacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (WAIHA) or Cold Agglutininin Disease (CAD)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.